News INmune Bio slumps on midstage fail for Alzheimer's drug INmune Bio's bid to develop an Alzheimer's drug with a new mechanism of action has been dented, but the company remains upbeat.
News Generic drugmaker Hikma pledges $1bn in US investment With tariffs looming, Indian drugmaker Hikma has said it will spend $1bn to expand its manufacturing and R&D operations in the US by 2030.
News FDA loosens restrictions on first-gen CAR-T therapies There is enough experience with the first wave of autologous CAR-T therapies to allow strict rules ensuring their safe use to be relaxed, says FDA.
News Neopharmed buys Euro rights to BioCryst's HAE drug Orladeyo Neopharmed Gentili buys BioCryst's hereditary angioedema drug Orladeyo in Europe, the first stage of an international expansion for the Italian firm.
News Novo Nordisk Foundation gives $75m for R&D 'challenges' The Novo Nordisk Foundation's latest round of R&D funding will go towards projects in biomanufacturing, cardiometabolic diseases, and AI.
News Controversial project aims to make artificial human genomes A landmark project funded by Wellcome aims to develop the tools needed to synthesise human genomes – and simultaneously probe the social implications.
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
